Prescribing Omnipod® 5
Simplify type 1 diabetes (T1D) care for young patients
Omnipod® 5 offers reassurance to parents and caregivers of children living with T1D, helping to protect against highs and lows and improving sleep quality compared to prior therapy.1-4
With Omnipod® 5, you can offer your young patients:
Set appropriate targets as your young patients’ needs change over time, with SmartAdjust™ technology to help protect them against highs and lows*†
Tubeless, waterproof‡, on-body, Automated Insulin Delivery (AID), so children can continue their AID when swimming or bathing
Improved outcomes vs prior therapy
Improved glycaemic outcomes that go hand-in-hand with improved quality of life and mental well-being reported by parents of children with T1D†1-3
† Results from two pivotal single-arm, multicentre, prospective studies in participants with T1D aged 6–70 years (112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years) and 80 very young children with T1D (2.0–5.9 years).1,2
‡ The Pod has a waterproof IP28 rating for up to 7.6 m (25 feet) for 60 minutes. The controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 m (8 feet) of water for up to 24 hours without failure when properly installed.
See the clinical evidence for yourself
The benefits of Omnipod® 5 in young people with T1D have been established in two pivotal, prospective clinical trials. Significant improvements in glycaemic control achieved with Omnipod® 5 vs prior therapy are accompanied by quality of life gains as reported by parents.*†1-4
† The Pod has a waterproof IP28 rating for up to 7.6 m (25 feet) for 60 minutes. The controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 m (8 feet) of water for up to 24 hours without failure when properly installed.
Which of your paediatric patients may benefit from Omnipod® 5?
Scared of needles
Emma, age 3
- The youngest child in her family, she is curious and joyful
- Diagnosed 3 months ago, on a multiple daily injection (MDI) regimen, but she is scared of needles
- Recently hospitalised for diabetic ketoacidosis (DKA)
Let’s meet Emma’s parents
- They are anxious about the intensity of Emma’s MDI regimen and do not like giving her injections
- They are challenged by wide glucose fluctuations and fearful of nocturnal hypoglycaemia causing sleep disruption
- Currently evaluating therapy options to help improve glycaemic control and promote safety
Omnipod® 5 may help Emma and her parents as it removes the need for daily injections and shows improved glycaemic control over standard therapy in very young children.1
Arrange a meeting with an Omnipod® representative
Do you have questions about Omnipod®? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod®.
Be the first to know
Stay up to date and be in the know when it comes to all things Insulet. By signing up for our mailing list, you will be in the know when it comes to training and events, Omnipod® published data and first-hand experiences from Podders®.
References: 1. Brown S et al. Diabetes Care 2021;44:1630-1640. 2. Sherr J et al. Diabetes Care 2022;45:1907-1910. 3. Sherr J et al. Evaluation of the Omnipod® 5 automated insulin delivery System in very young children with type 1 diabetes. Presented at the American Diabetes Association, June 21, 2021 virtual meeting. 4. Hood KK et al. Pediatric Diabetes 2023 [in press].